Welcome to our dedicated page for SAB BIOTHERAPEUTICS SEC filings (Ticker: SABS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SAB Biotherapeutics, Inc. (SAB BIO) SEC filings page for ticker SABS provides access to the company’s official regulatory disclosures as a clinical-stage biopharmaceutical issuer on Nasdaq. These documents are a primary source for detailed information on SAB BIO’s governance, equity structure, and other material corporate events related to its development of fully human immunoglobulin G (hIgG) and human anti-thymocyte immunoglobulin (hATG) therapies, including its lead program SAB-142 for autoimmune type 1 diabetes.
In SAB BIO’s Form 8-K filings, investors can find reports on matters such as Board of Directors changes and stockholder approvals. For example, one 8-K describes the resignation of two directors and a reduction in the size of the Board, noting that the departures were not due to disagreements over company operations, policies, or practices. Another 8-K details the results of a special meeting of stockholders, where stockholders approved amendments to the 2021 Omnibus Equity Incentive Plan, including increases in the maximum number of shares available under the plan and adjustments to the plan’s evergreen share increase, as well as approval of a proposal related to potential issuance of common stock upon conversion of Series B Convertible Preferred Stock under Nasdaq rules.
On Stock Titan, these and other SAB BIO filings are updated from the SEC’s EDGAR system and can be reviewed alongside AI-powered summaries. AI analysis helps explain complex items such as equity plan amendments, preferred stock conversion terms, and governance changes in clear language, saving time when reading lengthy forms. Users can quickly identify key sections of 8-Ks, 10-Ks, and 10-Qs, and can also monitor how equity incentives and capital structure decisions may relate to the company’s ongoing clinical development of SAB-142 and its broader human IgG platform.
For those researching SABS, this page centralizes SAB Biotherapeutics’ historical and current SEC reports, with tools to interpret the implications of each filing without manually parsing every line of legal and accounting text.
SAB Biotherapeutics (SABS) reports that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander disclose shared beneficial ownership of 3,432,153 shares of Common Stock, representing 5.1% of the class. The filing is a joint Schedule 13G statement dated April 30, 2026.
The percent of the class was calculated using 66,934,576 shares outstanding as of March 17, 2026 per the issuer's prospectus supplement. The reported shares are held through entities over which the reporting persons have shared voting and dispositive power, and a Joint Filing Agreement is attached.
SAB Biotherapeutics is holding its 2026 virtual annual stockholder meeting on June 18, 2026 at 10:00 a.m. Eastern via www.virtualshareholdermeeting.com/SABS2026. Stockholders will vote on electing four Class II directors for three-year terms and ratifying EisnerAmper LLP as independent auditor for 2026.
Holders of 50,951,037 shares of common stock of record on April 20, 2026 may vote online, by phone, mail or during the virtual meeting. The board describes its governance structure, committee membership, director independence, director compensation and major stockholders, and recommends voting “FOR” all director nominees and “FOR” auditor ratification.
SAB Biotherapeutics reported new Phase 1 data for its fully human anti-thymocyte globulin candidate SAB-142 in adults with established type 1 diabetes. In the six-person cohort, four participants received SAB-142 and two received placebo.
All four treated participants preserved C-peptide, with three classified as super responders showing increases above baseline through Day 120, while the placebo patient showed a decline consistent with disease progression. Treated participants’ continuous glucose monitoring time in range improved from 73% at baseline to 85% at Day 120 without higher exogenous insulin use.
Biomarker data indicated CD4+ T conventional cell exhaustion without immunodepletion, supporting SAB-142’s intended mechanism. A registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 type 1 diabetes is ongoing, with topline data expected in the second half of 2027.
SAB Biotherapeutics, Inc. chief medical officer Alexandra Kropotova reported a routine tax-related share withholding. On the vesting of restricted stock units, 988 shares of common stock were withheld to satisfy tax obligations, rather than sold in the market. After this disposition, she holds 43,296 shares directly, including 8,743 unvested RSUs, each representing a right to receive one share of common stock.
RA Capital Management and affiliates report beneficial ownership of 7,311,225 shares of SAB Biotherapeutics common stock, representing 9.9% of the class. The position includes common shares, Series B preferred stock, preferred stock warrants and pre-funded warrants, all subject to ownership limits.
On March 19, 2026, the RA Capital Healthcare Fund purchased pre-funded warrants to acquire 2,753,246 common shares at $3.8499 per warrant share, for an aggregate purchase price of $10,599,721.78 funded from its working capital. These pre-funded warrants are immediately exercisable at $0.0001 per share and do not expire, but contain a 9.99% beneficial ownership blocker.
SAB Biotherapeutics, Inc. entered into an underwriting agreement for an underwritten public offering of 19,324,677 common shares at $3.85 per share and pre-funded warrants to purchase up to 2,753,246 shares at $3.8499 per warrant. Gross proceeds are expected to be about $85 million, with estimated net proceeds of roughly $69.7 million, or $81.7 million if underwriters fully exercise a 30-day option for up to 3,311,688 additional shares. The company plans to use the cash, together with existing funds, primarily to advance its lead T1D candidate SAB-142 through ongoing and planned clinical trials, as well as related manufacturing, regulatory and general corporate needs.
SAB Biotherapeutics is offering 19,324,677 shares of common stock and, in lieu of shares to certain investors, pre-funded warrants to purchase up to 2,753,246 shares of common stock at a public offering price of $3.85 per share ($3.8499 per pre-funded warrant). The offering includes a 30-day underwriter option to purchase an additional 3,311,688 shares. Delivery is expected on or about March 19, 2026.
The company estimates net proceeds to the issuer of approximately $69.7 million (about $81.7 million if the option is exercised in full) and intends to use proceeds to fund continued development and clinical trials of its lead candidate, SAB-142, related manufacturing, regulatory and operational activities, and for working capital.
SAB Biotherapeutics is offering shares of common stock and pre-funded warrants in a shelf-based public offering. The prospectus supplement describes an offering of common stock and, in lieu of shares, pre-funded warrants exercisable for one share at an exercise price of $0.0001 per share. The company’s common stock trades on The Nasdaq Capital Market under the symbol SABS, and it reported 47,609,899 shares outstanding as of December 31, 2025. The prospectus references proceeds, underwriting arrangements, a 30-day option for additional shares, and customary underwriting terms; specific offering amounts and pricing are presented only in completed prospectus pages. The supplement also summarizes business and clinical developments: SAB-142 is the lead clinical candidate, the company received an IND clearance in May 2024, announced positive Phase 1 topline data across multiple dates including additional Phase 1 data on March 10, 2026, and is advancing SAB-142 into a Phase 2b SAFEGUARD study after a Type B meeting with the FDA on May 29, 2025.
RA Capital Management and affiliates report a 9.9% stake in SAB Biotherapeutics, Inc. common stock. They are deemed to beneficially own 5,166,424 shares of common stock, based on 50,951,037 shares outstanding as of March 2, 2026.
The Fund directly holds 4,401,500 common shares plus Series B preferred stock and warrants that are convertible or exercisable into additional common shares, subject to a Beneficial Ownership Blocker generally limiting ownership to 9.99% of outstanding stock. The cap can be raised up to 19.99% with 61 days’ notice.
The amendment clarifies that the reported increase in beneficial ownership results from a higher number of SAB Biotherapeutics shares outstanding, not from new purchases or sales. RA Capital also recommended David Zaccardelli, Pharm.D., and Rita Jain, M.D., who were appointed to the board on January 5, 2026.
SAB Biotherapeutics (SAB BIO) reported additional Phase 1 data for its lead Type 1 diabetes therapy SAB-142. In a small cohort of six adults with established Stage 3 T1D, four participants receiving SAB-142 at 2.5 mg/kg showed preserved or increased C-peptide levels at Day 120, while the single placebo completer showed a decline consistent with expected disease progression.
The company highlights biomarker evidence of T‑cell exhaustion supporting the drug’s intended mechanism and notes a previously established Phase 1 safety profile without serum sickness and with transient, reversible lymphopenia. These results supported advancing SAB-142 into the global registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 T1D patients, with topline data planned for the second half of 2027.